Prospective Evaluation of Forceplate Measured Levodopa-Induced Dyskinesia
1 other identifier
observational
10
1 country
1
Brief Summary
Nearly all Parkinson's disease (PD) patients eventually develop abnormal and unwanted movements (dyskinesias; LID) caused by the gold standard treatment, Levodopa. The severity of these movements can range from subtle to extremely debilitating and may or may not interfere with normal activities such as putting on a coat or brushing ones teeth. The purpose of this study is to demonstrate the validity and reliability of objectively measuring dyskinesia with a forceplate.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jun 2009
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2009
CompletedFirst Submitted
Initial submission to the registry
June 2, 2009
CompletedFirst Posted
Study publicly available on registry
June 3, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2010
CompletedSeptember 30, 2016
September 1, 2016
1 year
June 2, 2009
September 29, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Forceplate Measure
Every 1/2 hour
Secondary Outcomes (1)
Visual Rating Scale
every 1/2 hour
Study Arms (3)
Group 1
Groups are defined by another study
Group 2
Groups are defined by another study
Group 3
Groups are defined by another study
Eligibility Criteria
Parkinsons disease patients with levodopa-induced dyskinesia
You may qualify if:
- Parkinsons disease
- Older than 18
You may not qualify if:
- Must be participating in a Parkinsons disease study at Oregon Health \& Science University
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Oregon Health & Science University
Portland, Oregon, 97201, United States
Related Publications (3)
Durif F, Debilly B, Galitzky M, Morand D, Viallet F, Borg M, Thobois S, Broussolle E, Rascol O. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology. 2004 Feb 10;62(3):381-8. doi: 10.1212/01.wnl.0000110317.52453.6c.
PMID: 14872017BACKGROUNDHagell P, Widner H. Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale. Mov Disord. 1999 May;14(3):448-55. doi: 10.1002/1531-8257(199905)14:33.0.co;2-0.
PMID: 10348468BACKGROUNDDurif F, Vidailhet M, Debilly B, Agid Y. Worsening of levodopa-induced dyskinesias by motor and mental tasks. Mov Disord. 1999 Mar;14(2):242-5. doi: 10.1002/1531-8257(199903)14:23.0.co;2-w.
PMID: 10091616BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kathryn Chung, MD
Oregon Health and Science University
Study Design
- Study Type
- observational
- Observational Model
- CASE CROSSOVER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
June 2, 2009
First Posted
June 3, 2009
Study Start
June 1, 2009
Primary Completion
June 1, 2010
Study Completion
June 1, 2010
Last Updated
September 30, 2016
Record last verified: 2016-09